

Product Information


EPOXOMICIN

Product Number **E 3652**

Storage Temperature: -20 °C

CAS#: 134381-21-8

Synonyms: L-Threoninamide, N-acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-[(1S)-3-methyl-1-[(2R)-2-methyloxiranyl]carbonyl]butyl]; BU 4061T



Product Description

Molecular Weight: 554.7

Molecular Formula: C₂₈H₅₀N₄O₇

Epoxomicin, a natural product isolated from an *Actinomycetes* species, is an α^1 , β^1 -epoxy-ketone tetrapeptide proteasome inhibitor. It is a cell-permeable, potent, selective and irreversible proteasome inhibitor. It covalently binds to the catalytic β subunits of proteasome IFN- γ -inducible subunits LMP7 and MECL1 and their housekeeping respective counterparts X (MEB-1) and Z subunits.¹

Epoxomicin inhibits primarily chymotrypsin-like, but also trypsin-like, and peptidylglutamyl peptide-hydrolyzing (PGPH) activities of the proteasome.^{1,4} Epoxomicin is a more potent inhibitor of chymotrypsin-like activity of the proteasome than lactacystin, inhibiting the activity 80-fold faster than lactacystin.¹ Epoxomicin does not inhibit non-proteasomal proteases like calpain, chymotrypsin, trypsin, cathepsin B, or papain at concentrations of up to 50 μ M, unlike some peptide aldehyde proteasome inhibitors.^{1,4}

As a result of its selective and unique activity, it inhibits NF κ B activation *in vitro* and potently blocks *in vivo* inflammation in the murine ear edema assay.¹ Because NF κ is a key regulator of inflammation, Epoxomicin would be an attractive agent for antiinflammatory therapeutic intervention.

In addition, its proteasome inhibition results in modulation of antigen presentation with potential applications for treatment of autoimmune diseases and prevention of transplant rejection.² Epoxomicin also demonstrates antitumor activity.³

Precautions and Disclaimer

This product is for laboratory research use only. Please consult the Material Safety Data Sheet for handling recommendations before working with this material.

Preparation instructions

Epoxomicin is soluble in DMSO (10 mg/ml) and insoluble in water. Solutions can be stored at -20 °C for up to 3 months.

References

1. Meng, L., et al., Epoxomicin, a potent and selective proteasome inhibitor, exhibits *in vivo* antiinflammatory activity. Proc. Natl. Acad. Sci. USA, **96**, 10403-08 (1999).
2. Schwartz, K., et al., The selective proteasome inhibitors Lactacytin and Epoxomicin can be used to either up- or down-regulate antigen presentation in nontoxic doses. J. Immunol., **164**, 6147-57 (2000).
3. Sin, N. et al., Total synthesis of the potent proteasome inhibitor Epoxomicin: a useful tool for understanding proteasome biology. Bioorganic & Medicinal Chemistry Letters, **9**, 2283-88 (1999).
4. Princiotta, M. F., et al., Proc. Natl. Acad. Sci. USA, **98**, 513 (2001).

ARB/ARO 12/01

Sigma brand products are sold through Sigma-Aldrich, Inc.

Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see reverse side of the invoice or packing slip.